MedTrace Logo

An Open-Label Study to Assess Safety

NCT03645499 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2022-12-02

No results posted yet for this study

Summary

An Open-Label study to assess safety

Conditions

Interventions

DRUG

Topical TA-102 A

applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

DRUG

Topical TA-102 B

applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

DRUG

Topical TA-102 C

applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

DRUG

Topical TA-102 D

applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

DRUG

Topical TA-102 E

applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

Sponsors & Collaborators

  • Sun Pharmaceutical Industries, Inc.

    lead INDUSTRY

Principal Investigators

  • Natalie Yantovskiy · Taro Pharmaceuticals Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-04
Primary Completion
2019-10-24
Completion
2020-01-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03645499 on ClinicalTrials.gov